Utama › Penyakit Autoimun › Pennsylvania
Kajian klinikal Penyakit Autoimun di Pennsylvania
21 kajian untuk Penyakit Autoimun sedang mencari peserta di lokasi di Pennsylvania.
Bandar di Pennsylvania
Teks kajian rasmi (Bahasa Inggeris)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UPMC Hillman Cancer Center, Pittsburgh
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT03816345A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
- Lewis Katz School of Medicine at Temple University, Philadelphia
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06722235A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- Fox Chase Cancer Center- Temple BMT, Philadelphia
Mengambil pesertaFasa 2
Umur 16 hingga 70 · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07328581RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients, Philadelphia
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients, Pittsburgh
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients, Pittsburgh
Mengambil pesertaFasa 2/3
Umur 6 hingga 75 · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07103746A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
- Lewis Katz School of Medicine at Temple University, Philadelphia
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06948318A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Philadelphia
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06572384RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Children's Hospital of Philadelphia, Philadelphia
Mengambil pesertaFasa 1/2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06121297Abatacept for the Treatment of Giant Cell Arteritis
- University of Pennsylvania, Philadelphia
Mengambil pesertaFasa 3
Umur 50 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT04474847A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- The Children's Hospital of Philadelphia, Philadelphia
Mengambil pesertaFasa 3
Umur 12 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06056297KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Thomas Jefferson University Hospital, Philadelphia
Mengambil pesertaFasa 2/3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 29 Jul 2026 · NCT06193889A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Penn State Milton S. Hershey Cancer Center, Hershey
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh, Pittsburgh
- dan 3 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- University of Pennsylvania, Philadelphia
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Mei 2026 · NCT04422912A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Jefferson Einstein Hospital Philadelphia, Philadelphia
Mengambil pesertaFasa 1
Umur 12 hingga 70 · Semua jantina · Dikemas kini 22 Mei 2026 · NCT06308978Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting
- Magee-Womens Hospital, Pittsburgh
Mengambil peserta
Semua umur · Lelaki · Dikemas kini 22 Apr 2026 · NCT04452305Testicular Tissue Cryopreservation for Fertility Preservation
- Magee-Womens Hospital, Pittsburgh
Mengambil peserta
Semua umur · Lelaki · Dikemas kini 22 Apr 2026 · NCT02972801Ovarian Tissue Cryopreservation for Fertility Preservation
- Magee-Womens Hospital, Pittsburgh
Mengambil pesertaKajian pemerhatian
Sehingga umur 39 · Wanita · Dikemas kini 4 Mac 2026 · NCT05875155A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- Temple University Hospital, Philadelphia
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Feb 2026 · NCT06626919Central Vein Sign in Multiple Sclerosis Extension Study
- University of Pennsylvania, Philadelphia
Mengambil peserta
Umur 18 hingga 65 · Semua jantina · Dikemas kini 20 Feb 2026 · NCT07424027Autoimmunity After Checkpoint Blockade
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jan 2026 · NCT04119713X-linked Moesin Associated Immunodeficiency
- Perelman School of medecine, Philadelphia
Mengambil pesertaKajian pemerhatian
Umur 4 hingga 80 · Lelaki · Dikemas kini 25 Apr 2025 · NCT06278337Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.